パーキンソン病：グローバル医薬品市場予測及び分析（～2022）...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 9
1.1 List of Tables 16
1.2 List of Figures 22
2 Introduction 23
2.1 Catalyst 23
2.2 Related Reports 23
3 Disease Overview 24
3.1 Etiology and Pathophysiology 24
3.1.1 Etiology 24
3.1.2 Pathophysiology 27
3.1.3 Prognosis 29
3.1.4 Quality of Life 30
3.2 Symptoms 30
4 Epidemiology 32
4.1 Disease Background 32
4.2 Risk Factors and Comorbidities 32
4.2.1 The risk of developing Parkinson’s disease progressively increases with age 33
4.2.2 The risk for Parkinson’s disease is increased with Parkinson’s disease-causing mutations 34
4.2.3 Men are 1.5 times more likely to develop Parkinson’s disease than women, though the difference may be the result of varying exposures to environmental factors 34
4.2.4 Chemicals, along with exposure to other environmental factors, increase the risk of developing Parkinson’s disease 35
4.2.5 38% of Parkinson’s disease cases experienced depression and/or anxiety compared with only 8% of controls 35
4.3 Global and Historical Trends 36
4.3.1 US 36
4.3.2 5EU 37
4.3.3 Japan 37
4.3.4 Brazil 38
4.4 Forecast Methodology 39
4.4.1 Sources Used 40
4.4.2 Sources Not Used 43
4.4.3 Forecast Assumptions and Methods 43
4.5 Epidemiological Forecast of Parkinson’s Disease (2012-2022) 44
4.5.1 Prevalent Cases of Parkinson’s Disease 44
4.5.2 Age-Specific Prevalent Cases of Parkinson’s Disease 46
4.5.3 Sex-Specific Prevalent Cases of Parkinson’s Disease 48
4.5.4 Age-Standardized Prevalence of Parkinson’s Disease 49
4.6 Discussion 50
4.6.1 Epidemiological Forecast Insight 50
4.6.2 Limitations of the Analysis 51
4.6.3 Strengths of the Analysis 52
5 Disease Management 53
5.1 Overview 53
5.1.1 Diagnosis – The UK Brain Bank Criteria 53
5.1.2 Treatment Guidelines and Leading Prescribed Drugs 54
5.2 Treatment Synopsis 57
5.2.1 Dopaminergic Therapy Classes 57
5.2.2 Treatment of Parkinson’s Disease by Stage 59
5.2.3 Other Treatment Options 62
5.3 Parkinson’s Disease Assessment Scales 62
5.3.1 Unified Parkinson’s Disease Rating Scale (UPDRS) 63
5.3.2 Hoehn and Yahr Clinical Staging 65
5.3.3 Other Clinical Assessments 66
5.4 Diagnosis and Treatment of Parkinson’s Disease by Country 66
5.4.1 US 66
5.4.2 France 68
5.4.3 Germany 70
5.4.4 Italy 72
5.4.5 Spain 75
5.4.6 UK 77
5.4.7 Japan 78
5.4.8 Brazil 81
6 Competitive Assessment 84
6.1 Overview 84
6.2 Strategic Competitor Assessment 86
6.3 Product Profiles – Levodopa Combination Therapy 87
6.3.1 Madopar (levodopa/benserazide) 88
6.3.2 Sinemet (carbidopa/levodopa) 93
6.3.3 Duodopa (carbidopa/levodopa intestinal gel) 99
6.4 Product Profiles – COMT Inhibitors 103
6.4.1 Stalevo/Comtan (entacapone) 103
6.5 Dopamine Agonists 109
6.5.1 Neupro (rotigotine transdermal patch) 110
6.5.2 Requip/Requip XL (ropinirole) 117
6.5.3 Apokyn (apomorphine) 121
6.6 Product Profiles – MAO-B Inhibitors 126
6.6.1 Azilect (rasagiline) 127
6.7 Product Profiles – Adenosine 2A Inhibitor 133
6.7.1 Nouriast (istradefylline) 134
6.8 Product Profiles – Other Therapies 137
7 Opportunity and Unmet Need 139
7.1 Overview 139
7.2 Treatment of Motor Complications – Dyskinesias and OFF Episodes 141
7.2.1 Unmet Need 141
7.2.2 Gap Analysis 143
7.2.3 Opportunity 146
7.3 Treatment of Non-Motor Symptoms and Dementia 146
7.3.1 Unmet Need 146
7.3.2 Gap Analysis 147
7.3.3 Opportunity 149
7.4 Neuroprotective/Disease-Modifying Agents 149
7.4.1 Unmet Need 149
7.4.2 Gap Analysis 150
7.4.3 Opportunity 153
7.5 Improved Drug Formulations 154
7.5.1 Unmet Need 154
7.5.2 Gap Analysis 154
7.5.3 Opportunity 155
7.6 Identification of Reliable Biomarkers 155
7.6.1 Unmet Need 155
7.6.2 Gap Analysis 156
7.6.3 Opportunity 157
7.7 Improved Clinical Trial Design 157
7.7.1 Unmet Need 157
7.7.2 Gap Analysis 158
7.7.3 Opportunity 158
8 Pipeline Assessment 159
8.1 Overview 159
8.2 Clinical Trial Mapping 159
8.2.1 Clinical Trials by Class/Patient Population/Biomarkers/Line of Therapy 159
8.3 Promising Drugs in Clinical Development 161
8.3.1 Safinamide 163
8.3.2 Tozadenant 171
8.3.3 CVT-301 175
8.3.4 Rytary/IPX066 181
8.3.5 Opicapone 188
8.3.6 Mavoglurant/AFQ056 193
8.3.7 CD/LD-GR 196
8.3.8 Other Late-Stage Pipeline Products 201
9 Current and Future Players 202
9.1 Overview 202
9.2 Trends in Corporate Strategy 203
9.3 Company Profiles 204
9.3.1 Merck 204
9.3.2 Roche 206
9.3.3 AbbVie 208
9.3.4 UCB 210
9.3.5 GlaxoSmithKline 211
9.3.6 Novartis 213
9.3.7 Orion 216
9.3.8 Newron 217
9.3.9 Civitas 219
9.3.10 Impax 221
9.3.11 Lundbeck 223
10 Market Outlook 226
10.1 Global Markets 226
10.1.1 Forecast 226
10.1.2 Drivers and Barriers – Global Issues 230
10.2 US 232
10.2.1 Forecast 232
10.2.2 Key Events 237
10.2.3 Drivers and Barriers 237
10.3 France 239
10.3.1 Forecast 239
10.3.2 Key Events 243
10.3.3 Drivers and Barriers 243
10.4 Germany 245
10.4.1 Forecast 245
10.4.2 Key Events 249
10.4.3 Drivers and Barriers 249
10.5 Italy 251
10.5.1 Forecast 251
10.5.2 Key Events 255
10.5.3 Drivers and Barriers 255
10.6 Spain 257
10.6.1 Forecast 257
10.6.2 Key Events 262
10.6.3 Drivers and Barriers 262
10.7 UK 264
10.7.1 Forecast 264
10.7.2 Key Events 268
10.7.3 Drivers and Barriers 268
10.8 Japan 270
10.8.1 Forecast 270
10.8.2 Key Events 274
10.8.3 Drivers and Barriers 274
10.9 Brazil 276
10.9.1 Forecast 276
10.9.2 Key Events 280
10.9.3 Drivers and Barriers 280
11 Appendix 282
11.1 Bibliography 282
11.2 Abbreviations 300
11.3 Methodology 305
11.4 Forecasting Methodology 305
11.4.1 Diagnosed Parkinson’s Disease Patients 305
11.4.2 Percent Drug-Treated Patients 306
11.4.3 Drugs Included in Each Therapeutic Class 306
11.4.4 Launch and Patent Expiry Dates 307
11.4.5 General Pricing Assumptions 308
11.4.6 Compliance Assumptions 309
11.4.7 Individual Drug Assumptions 310
11.4.8 Generic Erosion 320
11.4.9 Pricing of Pipeline Agents 320
11.5 Physicians and Specialists Included in this Study 321
11.6 About the Authors 323
11.6.1 Author 323
11.6.2 Epidemiologist 324
11.6.3 Global Head of Healthcare 325
11.7 About GlobalData 326
11.8 Disclaimer 326